Harry Jr. Thomasian Sells 100,000 Shares of Precigen (NASDAQ:PGEN) Stock

Precigen, Inc. (NASDAQ:PGEN) CFO Harry Jr. Thomasian sold 100,000 shares of the stock in a transaction dated Friday, July 31st. The stock was sold at an average price of $6.06, for a total transaction of $606,000.00. Following the sale, the chief financial officer owned 254,535 shares of the company’s stock, valued at $1,542,482.10. This trade represents a 28.21% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Harry Jr. Thomasian also recently made the following trade(s):

• On Wednesday, July 1st, Harry Jr. Thomasian sold 171,429 shares of Precigen stock. The stock was sold at an average price of $5.53, for a total value of $948,002.37.
• On Monday, June 29th, Harry Jr. Thomasian sold 28,571 shares of Precigen stock. The shares were sold at an average price of $5.78, for a total value of $165,140.38.
• On Thursday, May 28th, Harry Jr. Thomasian sold 41,884 shares of Precigen stock. The shares were sold at an average price of $4.36, for a total value of $182,614.24.

Precigen Stock Performance

Precigen stock traded up $0.33 during mid-day trading on Friday, reaching $6.27. 5,613,108 shares of the company were exchanged, compared to its average volume of 4,460,619. Precigen, Inc. has a twelve month low of $1.63 and a twelve month high of $6.28. The firm’s 50-day simple moving average is $4.94 and its two-hundred day simple moving average is $4.39. The company has a debt-to-equity ratio of 4.62, a quick ratio of 4.12 and a current ratio of 4.82. The firm has a market cap of $2.24 billion, a PE ratio of -5.31 and a beta of 1.00.

Precigen (NASDAQ:PGEN) last released its earnings results on Wednesday, May 13th. The biotechnology company reported ($0.02) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.01. Precigen had a positive return on equity of 717.50% and a negative net margin of 646.99%.The business had revenue of $23.25 million for the quarter, compared to analyst estimates of $20.81 million. Equities analysts predict that Precigen, Inc. will post -0.02 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. State Street Corp increased its holdings in Precigen by 141.1% in the fourth quarter. State Street Corp now owns 10,824,860 shares of the biotechnology company’s stock valued at $45,248,000 after buying an additional 6,335,033 shares in the last quarter. SymBiosis Capital Partners LLC purchased a new stake in shares of Precigen during the 4th quarter worth approximately $12,540,000. Bank of America Corp DE boosted its stake in shares of Precigen by 201.1% during the 3rd quarter. Bank of America Corp DE now owns 2,505,992 shares of the biotechnology company’s stock worth $8,245,000 after acquiring an additional 1,673,731 shares in the last quarter. Goldman Sachs Group Inc. grew its holdings in shares of Precigen by 196.4% in the 4th quarter. Goldman Sachs Group Inc. now owns 2,173,933 shares of the biotechnology company’s stock worth $9,087,000 after acquiring an additional 1,440,446 shares during the period. Finally, Occam Crest Management LP increased its stake in Precigen by 29.6% in the 4th quarter. Occam Crest Management LP now owns 3,501,739 shares of the biotechnology company’s stock valued at $14,637,000 after purchasing an additional 799,339 shares in the last quarter. 33.51% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on PGEN shares. HC Wainwright boosted their price objective on shares of Precigen from $11.00 to $14.00 and gave the company a “buy” rating in a research note on Thursday, May 28th. Weiss Ratings restated a “sell (d-)” rating on shares of Precigen in a research report on Friday, July 17th. Wall Street Zen lowered Precigen from a “buy” rating to a “hold” rating in a report on Sunday, May 31st. Citigroup reiterated an “outperform” rating on shares of Precigen in a research report on Thursday, May 14th. Finally, Citizens Jmp raised their price target on Precigen from $9.00 to $11.00 and gave the company a “market outperform” rating in a report on Thursday, May 14th. Three investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $12.50.

Precigen Company Profile

Precigen, Inc (NASDAQ: PGEN) is a biotechnology company focused on the discovery, development and commercialization of genetic medicines. The company leverages proprietary gene and cell therapy platforms to design targeted therapies for oncology, infectious diseases and rare conditions. Precigen’s approach combines synthetic biology, immuno-oncology and microbiome engineering to create precision treatments intended to enhance efficacy while minimizing off-target effects.

The centerpiece of Precigen’s technology is its OmniCAR platform, which enables the rapid generation of adaptable chimeric antigen receptor (CAR) T-cell products.